Startup profile · funding coverage

Cartography Biosciences funding, valuation and investors

Oncology biotech building an antigen atlas for precise antibody immunotherapies.

Keep track of Cartography Biosciences

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$67M · 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$124M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · South San Francisco, California

Investors in latest funding

Lead: Pfizer Ventures

Other: 8VC , Andreessen Horowitz

Source links not recorded Last verified: 2026-07-25

Overview

Cartography Biosciences maps tumor-specific antigens across cancer types to design precise antibody immunotherapies — building an antigen atlas for oncology drug discovery.

Why Cartography Biosciences is interesting

Maps tumor-specific antigens systematically — 8VC-led Series A with a16z seed continuity into Pfizer Ventures-led Series B.

Product & use cases

Antigen atlas mapping tumor-specific antigens for precise antibody immunotherapies with reduced off-tumor toxicity.

Tumor antigen identification for oncology drug targets
Antibody therapy development with precision targeting
Reducing off-tumor toxicity in immunotherapy

Key facts

Series B (2025): $67M led by Pfizer Ventures; 8VC, Gaingels, a16z among existing investors (BusinessWire)
Series A (2022): $57M led by 8VC; a16z (seed lead) and Wing participated (a16z announcement)

Funding history (newest first)

Series B

2025 $67M

Series A

2022 $57M

Investors in our directory

Funds linked from Cartography Biosciences's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz 8VC Gaingels

Competitive landscape

Edge: Maps tumor-specific antigens systematically — 8VC-led Series A with a16z seed continuity into Pfizer Ventures-led Series B.

Cartography Biosciences operates in healthtech, biotech-life-sciences. Maps tumor-specific antigens systematically — 8VC-led Series A with a16z seed continuity into Pfizer Ventures-led Series B.

Bristol-Myers Squibb incumbent

Large pharma with oncology pipelines.
Genentech incumbent

Antibody therapeutics leader.
Other precision oncology biotechs direct

Competing antigen discovery approaches.

Notable stories

8VC-led Series A with a16z seed continuity.
Pfizer Ventures led $67M Series B in 2025.

Industries

Healthtech Biotech & Life Sciences

FAQs about Cartography Biosciences

Practical answers founders, operators, and investors typically search for.

Cartography systematically identifies antigens present on tumors but not healthy tissue, then develops antibody therapies against those targets for cancer treatment.

Andreessen Horowitz (see /fund/andreessen-horowitz) led the seed. 8VC (see /fund/8vc) led the $57M Series A; Pfizer Ventures led the $67M Series B in 2025 with a16z and 8VC re-upping.

Series B ($67M, 2025). The South San Francisco biotech remains private.

Precision oncology needs better target selection — Cartography's antigen atlas approach reduces off-tumor toxicity risk in antibody immunotherapy development.

No — Cartography Biosciences remains a private biotech.

Headquarters not publicly disclosed in sources we index.

Founding year not publicly disclosed in sources we index.

Cartography Biosciences has not publicly disclosed profitability.

See fundraising rounds and highlights on this profile for disclosed amounts.

healthtech, biotech-life-sciences

Website All startups Funding news

By Venture Capital Tracker

Last updated: July 25, 2026

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.